Navigation Links
Patients taking certolizumab pegol are twice as likely to achievE ACR20 compared to placebo
Date:6/7/2012

Berlin, Germany, June 7 2012: A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients treated with certolizumab pegol (CZP) were twice as likely to meet the primary endpoint of ACR20* response at week 12 than those on placebo: 58% on CZP200mg Q2W; and 51.9% on CZP 400 mg Q4W compared to 24.3% on placebo.

This randomised, placebo controlled, 24 week period of an ongoing Phase III study of 409 patients indicated that more patients treated with both doses of CZP achieved ACR50* and ACR70* response compared to placebo (CZP 200mg Q2W: 36.2%, CZP 400mg Q4W: 32.6%, PBO: 11% for ACR50, CZP 200mg Q2W: 24.6%, CZP 400mg Q4W: 12.6%, PBO: 2.9% for ACR70). HAQ-DI** scores were also higher in the combined CZP groups at week 24. In addition patients treated with both doses of CZP also showed greater improvements in PASI 75*** than placebo (62.2% and 60.5% respectively vs 15.1%).

"We know that certolizumab is effective in rheumatoid arthritis but this is the first study to review its efficacy and safety in psoriatic arthritis," commented Dr. Mease, University of Washington, USA and lead author of the study. "Not only were the signs and symptoms of arthritis improved, but so too were patients' physical function and skin manifestations, which is a great breakthrough for us and our patients."

The study followed 409 patients with active psoriatic arthritis who had failed one or more disease modifying anti-rheumatic drugs (DMARDs) including a maximum of one anti-TNF. Patients were randomised 1:1:1 to placebo, or started on a loading dose of 400mg CZP every two weeks for the first four weeks then continued either on 200mg CZP Q2W or 400mg CZP Q4W. Patients receiving placebo who failed to achieve a ≥10% improvement in tender joint count (TJC) and swollen joint count (SJC) at both weeks 14 and 16 were rescued and randomized to one of the CZP arms following loading dose.

CZP use in psoriatic arthritis was associated with a similar safety profile to what has been observed in rheumatoid arthritis. Adverse events occurred at the rates of 68% for the placebo group versus 62% for the combined CZP group, and serious adverse events at 4% for the placebo group versus 7% for the combined CZP group. Two deaths occurred during this 24 wk double-blind phase of the study, one sudden death of unknown cause (CZP 400mg Q4W) and one myocardial infarction (CZP 200mg Q2W).

Abstract Number: LB0001


'/>"/>

Contact: Candice Debleu
eularpressoffice@cohnwolfe.com
44-789-438-6425
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. ICU Patients at Risk for Rare Heart Rhythm Problem
2. Young patients with chronic illnesses find relief in acupuncture
3. For Some Breast Cancer Patients, Shorter Radiation Works Well
4. New Study Uses Adult Stem Cells in Effort to Save Limbs of Patients with Peripheral Arterial Disease
5. Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration
6. Behavioral therapy improves sleep and lives of patients with pain
7. Protecting patients: Study shows that Johns Hopkins flu vaccination rates twice national average
8. MSU researcher linking breast cancer patients with alternative therapies
9. New American Heart Association Survey Finds Heart Disease and Stroke Patients Face Significant Barriers in Obtaining Quality, Affordable Care
10. Fishy Smell May Keep Patients From Diabetes Drug
11. AGA offers new recommendations for CRC surveillance for certain patients with IBD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... (PRWEB) , ... February 26, ... ... sets a new technology standard in staffing, scheduling, and reporting for healthcare ... and predict activity throughout the entire staffing process. StaffBridge technology improves staffing ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... after receiving cognitive rehabilitation, according to a study released today at the 1st ... cognitive rehabilitation programs are proven to be effective in improving cognitive function in ...
(Date:2/25/2017)... (PRWEB) , ... February 25, 2017 , ... FCPX users ... Color tools from Pixel Film Studios. With ProSharpen Color users have total control over ... easily refine their color range. With color spectrum tools users can visually see the ...
(Date:2/24/2017)... ... February 24, 2017 , ... Houston ... options at his office, Antoine Dental Center. Currently, patients can get single dental ... may apply, but patients can learn more about these offers by contacting Antoine ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... business development, education, networking and recognition opportunities as well as advocacy for the ... in Holmdel, NJ on February 23. The Council's Innovation Forecast event highlights ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... TAMPA, Fla. , Feb. 27, 2017 /PRNewswire/ ... company focused on developing cerebral embolic protection devices ... of the FDA,s Circulatory System Devices Panel that ... the need for cerebral protection following transcatheter aortic ... shared by this FDA panel support the need ...
(Date:2/27/2017)... Feb. 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL ) today ... Raymond James and Associates, 38 th ... 2017 in Orlando, FL. Cowen ... ET on March 7, 2017 in Boston, MA. ... 16, 2017 in Miami, FL. ...
(Date:2/27/2017)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced ... President and Chief Executive Officer (CEO) and member of the ... Richard Love , interim President and CEO who will ... Craig has over 20 years of experience in hematology, oncology ... Europe . "On behalf of CTI BioPharma,s ...
Breaking Medicine Technology: